Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that data from four abstracts will be presented at the 39^th Annual Meeting of the Surgical Infection Society (SIS) taking place June 5-8, 2019 in Coronado, Calif. Presentations will include data on XERAVA^TM (eravacycline), a novel, fully synthetic fluorocycline approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI).

The details for the presentations at SIS are as follows:

Poster title: Factors That Impact Duration of Antibiotic Therapy From Phase 3 Studies of Eravacycline for Intra-Abdominal Infection
Presenter: Kenneth Lawrence, PharmD
Session: Bugs and Drugs
Date and time: Saturday, June 8 from 8:30 – 9:30 a.m. PT
Poster number: P24

Poster title: 2017 Global Surveillance of the In Vitro Activity of Eravacycline Against Clinical Isolates From Gastrointestinal Infections
Presenter: Steven Kolkin, PharmD
Session: Bugs and Drugs
Date and time: Saturday, June 8 from 8:30 – 9:30 a.m. PT
Poster number: P26

Poster title: Efficacy of Eravacycline in Non-Appendiceal Complicated Intra-Abdominal Infections: An Analysis of Two Phase 3 Trials
Presenter: Vanessa Grant-DiFelice, M.D.
Session: Bugs and Drugs
Date and time: Saturday, June 8 from 8:30 – 9:30 a.m. PT
Poster number: P28

Poster title: Microbiology and Outcomes of Hospitalization with Intra-Abdominal Infections in the U.S.: A Retrospective Cohort Study
Presenter: Melanie Olesky, Ph.D.
Session: Bugs and Drugs
Date and time: Saturday, June 8 from 8:30 – 9:30 a.m. PT
Poster number: P23

Additional Activities:

• Tetraphase will sponsor an luncheon symposium at SIS on Friday, June 7 from 12:00 – 1:15 p.m. PT located in Commodore E. Donald E. Fry M.D., will be leading the session with a talk titled "Getting it Wrong" in which he will discuss the impact of inappropriate empiric treatment for patients with cIAI. Vanessa Ho, M.D., will follow with a discussion focusing on a review of newer antibiotics for cIAI, titled "Getting it Right."
• Tetraphase will host a XERAVA exhibit booth (#2) at SIS during exhibit hours.

About XERAVA^TM